ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ASKA Pharmaceutical Holdings Co., Ltd. ?
1
Company has very low debt and has enough cash to service the debt requirements
2
Healthy long term growth as Operating profit has grown by an annual rate 28.74%
3
Flat results in Dec 25
- INTEREST(HY) At JPY 111 MM has Grown at 362.5%
- ROCE(HY) Lowest at 7.33%
- DEBT-EQUITY RATIO (HY) Highest at 10.38 %
4
With ROE of 8.27%, it has a very attractive valuation with a 1.08 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -3.70%, its profits have fallen by -28.4%
- At the current price, the company has a high dividend yield of 0
5
Underperformed the market in the last 1 year
- Even though the market (Japan Nikkei 225) has generated returns of 36.73% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -3.70% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ASKA Pharmaceutical Holdings Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ASKA Pharmaceutical Holdings Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
ASKA Pharmaceutical Holdings Co., Ltd.
-100.0%
-0.12
32.68%
Japan Nikkei 225
38.94%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.07%
EBIT Growth (5y)
28.74%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.17
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.87
Tax Ratio
17.62%
Dividend Payout Ratio
30.56%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.64%
ROE (avg)
11.79%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.08
EV to EBIT
13.13
EV to EBITDA
9.24
EV to Capital Employed
1.08
EV to Sales
1.09
PEG Ratio
NA
Dividend Yield
0.02%
ROCE (Latest)
8.20%
ROE (Latest)
8.27%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0.29% (YoY
NET SALES(Q)
Highest at JPY 19,233 MM
OPERATING PROFIT(Q)
Highest at JPY 3,031 MM
OPERATING PROFIT MARGIN(Q)
Highest at 15.76 %
PRE-TAX PROFIT(Q)
Highest at JPY 2,194 MM
NET PROFIT(Q)
Highest at JPY 1,678 MM
EPS(Q)
Highest at JPY 59.09
-15What is not working for the Company
INTEREST(HY)
At JPY 111 MM has Grown at 362.5%
ROCE(HY)
Lowest at 7.33%
DEBT-EQUITY RATIO
(HY)
Highest at 10.38 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.37 times
CASH AND EQV(HY)
Lowest at JPY 14,032 MM
Here's what is working for ASKA Pharmaceutical Holdings Co., Ltd.
Net Sales
Highest at JPY 19,233 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 3,031 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 15.76 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 2,194 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 1,678 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 59.09
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by 0.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for ASKA Pharmaceutical Holdings Co., Ltd.
Interest
At JPY 111 MM has Grown at 362.5%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Debt-Equity Ratio
Highest at 10.38 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 1.37 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Cash and Eqv
Lowest at JPY 14,032 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
